See more : StemCell Institute Inc. (7096.T) Income Statement Analysis – Financial Results
Complete financial analysis of Insmed Incorporated (INSM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Insmed Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- C5 Acquisition Corporation (CXAC-WT) Income Statement Analysis – Financial Results
- Maximus, Inc. (MMS) Income Statement Analysis – Financial Results
- Stanpacks (India) Limited (STANPACK.BO) Income Statement Analysis – Financial Results
- Peab AB (publ) (PEAB-B.ST) Income Statement Analysis – Financial Results
- Treasury Metals Inc. (TRYMF) Income Statement Analysis – Financial Results
Insmed Incorporated (INSM)
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 305.21M | 245.36M | 188.46M | 164.41M | 136.47M | 9.84M | 0.00 | 0.00 | 0.00 | 11.50M | 11.50M | 0.00 | 4.42M | 6.92M | 10.37M | 11.70M | 7.53M | 991.00K | 131.00K | 137.00K | 150.00K | 1.96M | 296.00K | 60.00K | 663.16K |
| Cost of Revenue | 65.57M | 55.13M | 44.15M | 39.87M | 24.21M | 2.42M | 2.90M | 2.44M | 1.98M | 33.53M | 29.64M | 21.37M | 0.00 | 0.00 | 0.00 | 0.00 | 576.00K | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -86.57K |
| Gross Profit | 239.64M | 190.23M | 144.31M | 124.54M | 112.26M | 7.41M | -2.90M | -2.44M | -1.98M | -22.03M | -18.14M | -21.37M | 4.42M | 6.92M | 10.37M | 11.70M | 6.95M | -499.00K | 131.00K | 137.00K | 150.00K | 1.96M | 296.00K | 60.00K | 749.74K |
| Gross Profit Ratio | 78.52% | 77.53% | 76.57% | 75.75% | 82.26% | 75.36% | 0.00% | 0.00% | 0.00% | -191.61% | -157.77% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 92.35% | -50.35% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 113.05% |
| Research & Development | 571.01M | 397.52M | 272.74M | 181.16M | 131.71M | 145.28M | 109.75M | 122.72M | 74.28M | 56.29M | 44.28M | 29.78M | 27.92M | 4.76M | 9.21M | 21.05M | 18.94M | 21.09M | 21.84M | 23.32M | 7.14M | 18.08M | 35.51M | 21.61M | 6.35M |
| General & Administrative | 344.50M | 244.98M | 234.27M | 203.61M | 210.80M | 168.22M | 79.17M | 50.68M | 43.22M | 31.07M | 22.24M | 12.66M | 12.23M | 10.26M | 0.00 | 0.00 | 0.00 | 0.00 | 5.73M | 2.98M | 3.48M | 2.98M | 4.98M | 9.55M | 0.00 |
| Selling & Marketing | 0.00 | 20.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 344.50M | 265.78M | 234.27M | 203.61M | 210.80M | 168.22M | 79.17M | 50.68M | 43.22M | 31.07M | 22.24M | 12.66M | 12.23M | 10.26M | 9.84M | 5.06M | 8.46M | 25.68M | 5.73M | 4.24M | 3.48M | 2.98M | 4.98M | 9.55M | 2.44M |
| Other Expenses | 33.75M | 5.05M | 5.05M | 5.00M | 4.99M | 602.00K | 300.00K | 119.00K | -33.00K | 141.00K | -33.00K | 0.00 | 12.23M | 10.26M | 9.84M | 5.06M | 8.46M | 32.79M | 5.73M | 4.24M | 3.60M | 18.37M | 95.00K | 0.00 | 2.53M |
| Operating Expenses | 949.26M | 668.36M | 512.07M | 389.77M | 347.50M | 314.75M | 188.92M | 173.40M | 117.49M | 87.37M | 66.52M | 42.44M | 40.15M | 15.01M | 19.05M | 26.11M | 27.39M | 53.87M | 27.57M | 27.56M | 10.74M | 36.45M | 40.48M | 31.16M | 8.88M |
| Cost & Expenses | 1.01B | 723.48M | 556.22M | 429.65M | 371.71M | 317.17M | 188.92M | 173.40M | 117.49M | 87.37M | 66.52M | 42.44M | 40.15M | 15.01M | 19.05M | 26.11M | 27.97M | 55.36M | 27.57M | 27.56M | 10.74M | 36.45M | 40.48M | 31.16M | 8.79M |
| Interest Income | 0.00 | 11.08M | 174.00K | 1.70M | 9.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.85M | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 607.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 81.69M | 26.45M | 40.47M | 29.56M | 27.71M | 25.47M | 5.93M | 3.50M | 2.89M | 2.42M | 2.41M | 763.00K | 10.00K | 109.00K | 781.00K | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.58M | 24.27M | 27.85M | 20.08M | 10.18M | 4.83M | 2.90M | 2.44M | 1.98M | 1.07M | 680.00K | 561.00K | 343.00K | 54.00K | 707.00K | 1.04M | 406.00K | 3.37M | 12.90M | 34.00K | 96.00K | 346.00K | 1.54M | 789.00K | 86.57K |
| EBITDA | -660.18M | -429.44M | -375.09M | -250.37M | -215.67M | -293.78M | -184.10M | -170.24M | -115.28M | -86.09M | -54.20M | -40.05M | -59.31M | -6.19M | 120.32M | -13.37M | -18.87M | -49.07M | -13.79M | -27.17M | -10.49M | -34.15M | -38.64M | -30.31M | -8.04M |
| EBITDA Ratio | -216.30% | -186.75% | -198.12% | -158.03% | -169.11% | -3,106.12% | 0.00% | 0.00% | 0.00% | -758.47% | -472.77% | 0.00% | -801.13% | -116.14% | -76.81% | -109.99% | -266.08% | -4,429.97% | -11,096.95% | -19,993.43% | -6,914.00% | -830.03% | -13,055.41% | 33,536.67% | -1,212.93% |
| Operating Income | -709.63M | -478.12M | -367.76M | -265.23M | -235.25M | -307.34M | -188.92M | -173.40M | -117.49M | -87.37M | -55.02M | -42.44M | -61.72M | -8.09M | -8.67M | -14.41M | -20.44M | -54.37M | -27.43M | -27.43M | -10.59M | -37.02M | -40.19M | -81.54M | -8.13M |
| Operating Income Ratio | -232.51% | -194.87% | -195.14% | -161.32% | -172.38% | -3,124.94% | 0.00% | 0.00% | 0.00% | -759.70% | -478.39% | 0.00% | -1,397.31% | -116.92% | -83.62% | -123.18% | -271.47% | -5,486.68% | -20,941.98% | -20,018.25% | -7,057.33% | -1,893.81% | -13,576.35% | -135,891.67% | -1,225.98% |
| Total Other Income/Expenses | -37.39M | -2.03M | -61.32M | -27.46M | -18.32M | -16.74M | -4.00M | -2.78M | -2.66M | -2.22M | -2.28M | -1.14M | -23.94M | 1.74M | 127.50M | -1.26M | 477.00K | -1.77M | -13.50M | 222.00K | 288.00K | 607.00K | 3.02M | 1.87M | 0.00 |
| Income Before Tax | -747.01M | -480.15M | -436.41M | -292.69M | -253.56M | -324.08M | -192.92M | -176.18M | -120.15M | -89.58M | -57.29M | -41.37M | -59.66M | -6.36M | 118.83M | -15.67M | -19.96M | -56.14M | -40.93M | -36.42M | -10.30M | -36.42M | -37.17M | -79.66M | 0.00 |
| Income Before Tax Ratio | -244.76% | -195.69% | -231.57% | -178.02% | -185.80% | -3,295.13% | 0.00% | 0.00% | 0.00% | -778.97% | -498.21% | 0.00% | -1,350.78% | -91.84% | 1,145.54% | -133.92% | -265.13% | -5,664.88% | -31,243.51% | -26,581.75% | -6,865.33% | -1,862.76% | -12,557.09% | -132,770.00% | 0.00% |
| Income Tax Expense | 2.56M | 1.38M | -1.76M | 1.40M | 777.00K | 201.00K | -272.00K | 98.00K | -1.97M | -10.42M | -1.22M | 763.00K | 9.18M | 78.00K | 477.00K | 1.26M | 0.00 | 1.77M | 0.00 | -9.21M | -288.00K | 1.93M | -74.34M | 200.00K | -337.57K |
| Net Income | -749.57M | -481.53M | -434.65M | -294.09M | -254.34M | -324.28M | -192.65M | -176.27M | -118.18M | -79.16M | -56.07M | -41.37M | -59.66M | -6.43M | 118.35M | -15.67M | -19.96M | -56.14M | -40.93M | -27.20M | -10.30M | -36.42M | -37.17M | -79.86M | -7.79M |
| Net Income Ratio | -245.59% | -196.26% | -230.63% | -178.87% | -186.37% | -3,297.17% | 0.00% | 0.00% | 0.00% | -688.34% | -487.59% | 0.00% | -1,350.78% | -92.96% | 1,140.94% | -133.92% | -265.13% | -5,664.88% | -31,243.51% | -19,856.20% | -6,865.33% | -1,862.76% | -12,557.09% | -133,103.33% | -1,175.08% |
| EPS | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.56 | -0.49 | 9.30 | -1.28 | -1.74 | -5.89 | -8.40 | -6.95 | -2.89 | -11.01 | -11.31 | -43.60 | -24.70 |
| EPS Diluted | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.56 | -0.49 | 9.30 | -1.28 | -1.74 | -5.89 | -8.40 | -6.95 | -2.89 | -11.01 | -11.31 | -43.60 | -24.70 |
| Weighted Avg Shares Out | 140.43M | 123.04M | 112.11M | 97.61M | 84.56M | 76.84M | 66.58M | 61.85M | 58.51M | 43.02M | 34.98M | 26.52M | 23.35M | 13.25M | 12.71M | 12.21M | 11.47M | 9.53M | 4.87M | 3.92M | 3.56M | 3.31M | 3.29M | 1.83M | 315.50K |
| Weighted Avg Shares Out (Dil) | 140.43M | 123.04M | 112.11M | 97.61M | 84.56M | 76.89M | 66.58M | 61.89M | 58.63M | 43.10M | 34.98M | 26.55M | 23.35M | 13.25M | 12.73M | 12.21M | 11.47M | 9.53M | 4.87M | 3.92M | 3.56M | 3.31M | 3.29M | 1.83M | 315.50K |
Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022— —Company Reiterates Full-Year 2023 Guidance Range for...
Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI
BRIDGEWATER, N.J. , Oct. 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, today announced a collaboration with Google Cloud to transform the drug discovery, development, and commercialization landscape of the life sciences industry through the use of...
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023
BRIDGEWATER, N.J. , Oct. 12, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third-quarter 2023 financial results...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Oct. 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 16 new...
Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference
BRIDGEWATER, N.J. , Sept. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat...
Why Shares of Insmed Are Soaring This Week
Insmed is looking to broaden the use of its only approved therapy, Arikayce. The company had a record $72 million in revenue in the second quarter.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Sept. 8, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 13 new employees.
Insmed (INSM) Up on Positive Data From MAC Lung Disease Study
Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.
Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BRIDGEWATER, N.J. , Sept. 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at...
Source: https://incomestatements.info
Category: Stock Reports